S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.42 (+0.90%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.42 (+0.90%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
Log in

Iterum Therapeutics News Headlines (NASDAQ:ITRM)

$3.66
+0.30 (+8.93 %)
(As of 10/21/2019 04:00 PM ET)
Today's Range
$3.52
Now: $3.66
$3.66
50-Day Range
$3.65
MA: $5.76
$6.96
52-Week Range
$3.36
Now: $3.66
$9.30
Volume23,200 shs
Average Volume10,735 shs
Market Capitalization$51.09 million
P/E RatioN/A
Dividend YieldN/A
Beta2.01

Headlines

Iterum Therapeutics (NASDAQ ITRM) News Headlines

Source:
DateHeadline
Iterum Therapeutics PLC (NASDAQ:ITRM) Receives Average Rating of "Buy" from AnalystsIterum Therapeutics PLC (NASDAQ:ITRM) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - October 9 at 1:48 AM
Iterum Therapeutics PLC (NASDAQ:ITRM) Short Interest Down 5.6% in SeptemberIterum Therapeutics PLC (NASDAQ:ITRM) Short Interest Down 5.6% in September
www.americanbankingnews.com - September 30 at 12:54 PM
Iterum Therapeutics to Present at the Cantor Fitzgerald Global Healthcare ConferenceIterum Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 27 at 5:23 PM
If You Had Bought Iterum Therapeutics (NASDAQ:ITRM) Stock A Year Ago, Youd Be Sitting On A 17% Loss, TodayIf You Had Bought Iterum Therapeutics (NASDAQ:ITRM) Stock A Year Ago, You'd Be Sitting On A 17% Loss, Today
finance.yahoo.com - September 9 at 10:14 PM
If You Had Bought Iterum Therapeutics (NASDAQ:ITRM) Stock A Year Ago, You'd Be Sitting On A 17% Loss, TodayIf You Had Bought Iterum Therapeutics (NASDAQ:ITRM) Stock A Year Ago, You'd Be Sitting On A 17% Loss, Today
finance.yahoo.com - September 9 at 5:11 PM
Iterum Therapeutics EPS misses by $0.35, misses on revenueIterum Therapeutics EPS misses by $0.35, misses on revenue
seekingalpha.com - August 14 at 11:05 AM
Iterum Therapeutics Reports Second Quarter 2019 Financial ResultsIterum Therapeutics Reports Second Quarter 2019 Financial Results
finance.yahoo.com - August 14 at 11:05 AM
Iterum Therapeutics PLC (ITRM) Reports Q2 Loss, Misses Revenue EstimatesIterum Therapeutics PLC (ITRM) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - August 14 at 11:05 AM
Checking In On Iterum TherapeuticsChecking In On Iterum Therapeutics
seekingalpha.com - August 7 at 6:20 PM
Iterum Therapeutics PLC (ITRM) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseIterum Therapeutics PLC (ITRM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
finance.yahoo.com - August 6 at 12:12 PM
Iterum Therapeutics to Present at the Canaccord Genuity 39th Annual Growth ConferenceIterum Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
finance.yahoo.com - August 1 at 9:57 AM
Who Has Been Buying Iterum Therapeutics plc (NASDAQ:ITRM) Shares?Who Has Been Buying Iterum Therapeutics plc (NASDAQ:ITRM) Shares?
finance.yahoo.com - July 10 at 3:48 PM
Iterum Therapeutics to Present Data on Uncomplicated Urinary Tract Infections at ASM Microbe 2019Iterum Therapeutics to Present Data on Uncomplicated Urinary Tract Infections at ASM Microbe 2019
finance.yahoo.com - June 21 at 9:27 AM
Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019
finance.yahoo.com - June 20 at 11:27 AM
Iterum Therapeutics Reports First Quarter 2019 Financial ResultsIterum Therapeutics Reports First Quarter 2019 Financial Results
finance.yahoo.com - May 14 at 12:16 PM
Iterum Therapeutics Presents Data on Risks for Treatment Failure Associated with Uncomplicated Urinary Tract Infection and Activity of its Novel Antibiotic Sulopenem at ECCMID 2019Iterum Therapeutics Presents Data on Risks for Treatment Failure Associated with Uncomplicated Urinary Tract Infection and Activity of its Novel Antibiotic Sulopenem at ECCMID 2019
finance.yahoo.com - April 11 at 8:22 AM
Will Iterum Therapeutics Continue to Surge Higher?Will Iterum Therapeutics Continue to Surge Higher?
finance.yahoo.com - March 28 at 12:38 PM
Iterum Therapeutics PLC (ITRM) Moves to Buy: Rationale Behind the UpgradeIterum Therapeutics PLC (ITRM) Moves to Buy: Rationale Behind the Upgrade
finance.yahoo.com - March 28 at 12:38 PM
Iterum Therapeutics Reports Fourth Quarter and Full Year 2018 Financial ResultsIterum Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
finance.yahoo.com - March 25 at 12:10 PM
Iterum Therapeutics PLCIterum Therapeutics PLC
www.barrons.com - March 19 at 4:05 PM
Iterum Therapeutics up 27% on expanded QIDP status for sulopenemIterum Therapeutics up 27% on expanded QIDP status for sulopenem
seekingalpha.com - March 19 at 4:05 PM
Iterum Therapeutics Receives QIDP for Oral and IV Sulopenem in Four Additional Indications as well as Fast Track DesignationIterum Therapeutics Receives QIDP for Oral and IV Sulopenem in Four Additional Indications as well as Fast Track Designation
finance.yahoo.com - March 19 at 10:49 AM
What Kind Of Shareholders Own Iterum Therapeutics plc (NASDAQ:ITRM)?What Kind Of Shareholders Own Iterum Therapeutics plc (NASDAQ:ITRM)?
finance.yahoo.com - February 21 at 1:31 PM
Iterum to Present at the 8th Annual SVB Leerink Partners Global Healthcare ConferenceIterum to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference
finance.yahoo.com - February 19 at 12:23 PM
Are Insiders Buying Iterum Therapeutics plc (NASDAQ:ITRM) Stock?Are Insiders Buying Iterum Therapeutics plc (NASDAQ:ITRM) Stock?
finance.yahoo.com - December 20 at 3:33 PM
Form 8-K Iterum Therapeutics plc For: Nov 14Form 8-K Iterum Therapeutics plc For: Nov 14
www.streetinsider.com - November 14 at 3:25 PM
Iterum Therapeutics beats by $0.73, beats on revenueIterum Therapeutics beats by $0.73, beats on revenue
seekingalpha.com - November 14 at 9:36 AM
Iterum Reports Third Quarter 2018 Financial Results and Recent HighlightsIterum Reports Third Quarter 2018 Financial Results and Recent Highlights
finance.yahoo.com - November 14 at 9:36 AM
Iterum Therapeutics plc to Participate in Investor Conferences in November and DecemberIterum Therapeutics plc to Participate in Investor Conferences in November and December
finance.yahoo.com - November 6 at 9:31 AM
Iterum Therapeutics Presents Data Highlighting Antibiotic Sulopenem at IDWeek 2018Iterum Therapeutics Presents Data Highlighting Antibiotic Sulopenem at IDWeek 2018
finance.yahoo.com - October 5 at 8:30 AM
Iterum to Present at Cantor Fitzgerald Global Healthcare ConferenceIterum to Present at Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 26 at 8:33 AM
Iterum Therapeutics Plc (ITRM) Commences SURE 2 & SURE 3 Phase 3 Clinical Trials of IV and Oral SulopenemIterum Therapeutics Plc (ITRM) Commences SURE 2 & SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem
www.streetinsider.com - September 20 at 8:10 AM
Iterum Therapeutics to Present Clinical Data on Antibiotic Sulopenem at IDWeek 2018Iterum Therapeutics to Present Clinical Data on Antibiotic Sulopenem at IDWeek 2018
finance.yahoo.com - September 20 at 8:10 AM
Iterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in ComplicatedIterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in Complicated
www.nasdaq.com - September 18 at 3:20 PM
Iterm launches two late-stage studies on antibiotic sulopenem; shares up 5%Iterm launches two late-stage studies on antibiotic sulopenem; shares up 5%
seekingalpha.com - September 18 at 3:20 PM
Iterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal InfectionsIterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal Infections
finance.yahoo.com - September 18 at 3:20 PM
Iterum Reports Second Quarter 2018 Financial Results and Recent HighlightsIterum Reports Second Quarter 2018 Financial Results and Recent Highlights
finance.yahoo.com - August 14 at 3:19 PM
SPRO To Report Data In Q3, ITRM Takes Steady And SURE Steps, PBYI On WatchSPRO To Report Data In Q3, ITRM Takes Steady And SURE Steps, PBYI On Watch
www.nasdaq.com - August 10 at 7:25 AM
Iterum Initiates SURE 1, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract InfectionsIterum Initiates SURE 1, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
finance.yahoo.com - August 10 at 7:25 AM
Iterum Therapeutics to Present Data on Prevalence of Resistant Infections and In Vitro Activity of its Novel Antibiotic SulopenemIterum Therapeutics to Present Data on Prevalence of Resistant Infections and In Vitro Activity of its Novel Antibiotic Sulopenem
finance.yahoo.com - June 6 at 3:15 PM
Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018
finance.yahoo.com - June 6 at 3:15 PM
[$$] Drugmaker Iterum Therapeutics Bags $80 Million in IPO[$$] Drugmaker Iterum Therapeutics Bags $80 Million in IPO
finance.yahoo.com - June 1 at 10:33 AM
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Featured Article: High-Yield Dividend Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel